How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Sonrotoclax (drug), Zanubrutinib (drug), Acalabrutinib (drug), Venetoclax (drug)
How long the study runs: Study runs about 70 months (dates as stated)
About the drug or intervention: Sonrotoclax — drug: Administered orally. · Zanubrutinib — drug: Administered orally. · Acalabrutinib — drug: Administered orally. · Venetoclax — drug: Administered orally.
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 500
Started: 2026-01-22
Last checked: 2026-09

Plain English Summary

What is this study?

• Testing a new treatment for chronic lymphocytic leukemia
• Phase3 - 500 participants
• The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL)

Who can take part?

• Ages 18 Years and over
• Diagnosed with chronic lymphocytic leukemia

Where?

• Birmingham - Queen Elizabeth Hospital
• Bournemouth - University Hospitals Dorset Royal Bournemouth Hospital
• Leeds - St Jamess University Hospital
• London - Kings College Hospital
• +1 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Chronic Lymphocytic Leukemia

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

Treatment history

Treatments you must have had:

✓ treatment

What the study is looking for

✓Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
✓activity scale (ECOG) score 0, 1, or 2
✓cancer that can be measured on scans by Computer Tomography/Magnetic Resonance Imaging
✓Adequate bone marrow and organ health

Who cannot take part

✗Previous systemic treatment for CLL
✗Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
✗Known central nervous system involvement
✗History of confirmed progressive multifocal leukoencephalopathy (PML)
✗Uncontrolled hypertension or clinically significant cardiovascular disease

See the full criteria

Inclusion Criteria: * Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment * Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2 * Measurable disease by Computer Tomography/Magnetic Resonance Imaging * Adequate bone marrow and organ function Exclusion Criteria: * Previous systemic treatment for CLL * Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation * Known central nervous system involvement * History of confirmed progressive multifocal leukoencephalopathy (PML) * Uncontrolled hypertension or clinically significant cardiovascular disease Note: Other protocol defined Inclusion/Exclusion criteria may apply.